Reference - Detail
| RRC ID | 65640 |
|---|---|
| Author | Furuyama F, Koba S, Yokota Y, Tsunoda F, Shoji M, Kobayashi Y. |
| Title | Effects of Cardiac Rehabilitation on High-Density Lipoprotein-mediated Cholesterol Efflux Capacity and Paraoxonase-1 Activity in Patients with Acute Coronary Syndrome. |
| Journal | J Atheroscler Thromb |
| Abstract |
AIMS:We evaluated whether exercised-based cardiac rehabilitation (CR) can ameliorate the HDL function, i.e., cholesterol efflux capacity (CEC) and paraoxonase-1 activity in patients with acute coronary syndrome (ACS). METHODS:This study is a retrospective analysis of stored serum from patients with ACS following successful percutaneous coronary intervention. The CEC, measured by a cell-based ex vivo assay using apolipoprotein B-depleted serum and 3H-cholesterol labeled macrophages and arylesterase activity (AREA) at the onset or early phase of ACS, and the follow-up periods were compared between 69 patients who completed the five-month outpatient CR program (CR group) and 15 patients who did not participate and/or dropped out from CR program (non-CR group). RESULTS:Apolipoprotein A-I (apoA-I) and CEC significantly increased by 4.0% and 9.4%, respectively, in the CR group, whereas HDL-cholesterol and AREA were not changed during the follow-up periods in both groups. Among CR patients, the CEC significantly increased, irrespective of the different statin treatment, while HDL-cholesterol and apoA-I significantly increased in patients treated with rosuvastatin or pitavastatin. Although CEC and AREA were significantly correlated each other, there is a discordance between CEC and AREA for their correlations with other biomarkers. Both CEC and AREA were significantly correlated with apoA-I rather than HDL-cholesterol. Changes in CEC and those in AREA were significantly correlated with those in apoA-I (rho=0.328, p=0.002, and rho=0.428, p＜0.0001, respectively) greater than those in HDL-cholesterol (rho=0.312, p= 0.0042,and rho=0.343, p=0.003, respectively). CONCLUSIONS:CR can improve HDL function, and it is beneficial for secondary prevention. |
| Volume | 25(2) |
| Pages | 153-169 |
| Published | 2018-2-1 |
| DOI | 10.5551/jat.41095 |
| PMID | 28855433 |
| PMC | PMC5827085 |
| MeSH | Acute Coronary Syndrome / drug therapy Acute Coronary Syndrome / metabolism* Acute Coronary Syndrome / rehabilitation Aged Anticholesteremic Agents / pharmacology Aryldialkylphosphatase / metabolism* Biomarkers / metabolism* Cardiac Rehabilitation / methods* Cholesterol, HDL / metabolism* Female Follow-Up Studies Humans Male Middle Aged Prognosis Retrospective Studies |
| IF | 3.876 |
| Resource | |
| Human and Animal Cells | J774.1 |